Navigation Links
MDS Pharma Services Launches Next Generation Phase I Study Management System
Date:7/7/2008

Proprietary ClinQuick(R) system builds on a 15-year track record of

technical leadership in early clinical research

KING OF PRUSSIA, PA, July 7 /PRNewswire-FirstCall/ - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has launched the next generation of its proprietary ClinQuick(R) electronic system for Phase I study set-up, data capture, project tracking and personnel credential management. Aimed at improving client service, the new version of the ClinQuick(R) system extends a 15-year legacy of technical leadership in early clinical research. System enhancements include a more user-friendly interface, improved menu navigation and a more robust data platform. This new platform will enable faster and more flexible reporting and will ultimately allow clients to access their data via the internet.

"Since its implementation in 1993, ClinQuick(R) has been used successfully in more than 3,000 Phase I studies involving nearly 100,000 participants," said MDS Pharma Services President David Spaight. "Our investment to enhance the ClinQuick(R) system builds on that legacy of success and will allow us to meet growing client demand for early clinical research services while maintaining our leadership position in Phase I. This next-generation ClinQuick(R) system will further improve our ability to deliver high quality Phase I services on time."

About ClinQuick(R)

Designed and built by MDS Pharma Services for use in its Phase I clinical research centers, the fully integrated ClinQuick(R) system facilitates rapid data cleansing and client monitoring for seamless operation of both single and multi-site studies. ClinQuick(R) accelerates timelines, enables accurate direct data acquisition, and reduces costs by a third compared to traditional paper case report forms (CRFs) - the forms used by clients to collect and document data from each participating clinical research site. The system i
'/>"/>

SOURCE MDS Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 24, 2013 On March 14, 2012, ... women will hear in her lifetime: she had breast cancer. ... Journey After a Breast Cancer Diagnosis ” (published by AuthorHouse), ... , Rideout drew from her daily journals to give readers ... surgery, chemotherapy and radiation treatments to deal with stage two ...
(Date:5/23/2013)... If you are one of the estimated ... the food spread this Memorial Day weekend could put ... dogs and ice cream have become cornerstones of the ... sufferers often feel the painful effects of consuming these ... Lourdes Medical Associates. , IBS occurs when the large ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Amirsys, ... comprehensive radiology learning environment for all resident levels ... and assessments, transforms the learning experience from case-based ... , “Until RADPrimer 3.0, RADPrimer heavily ... none,” comments Dr. B.J. Manaster, Professor of Radiology ...
(Date:5/23/2013)... 2013)Don,t doubt it when a woman harried by hot ... A new study published online in Menopause , ... helps confirm with objective tests that what these women ... past, some studies showed that hot flashes were related ... that, even though there was a relationship between hot ...
(Date:5/23/2013)... being dragged to its destruction inside a cell, ... signals that thwart the development of tumor-suppressing microRNAs ... early online publication at Nature . , ... tumors, the epidermal growth factor receptor (EGFR) gums ... led by scientists at The University of Texas ...
Breaking Medicine News(10 mins):Health News:Kimberley Rideout Shares Her Triumphant Cancer Survival Story 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 3Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3
... WASHINGTON, Dec. 18 - In response to the,press ... E. Schumer (D-NY) of a bill -- S ... (DARA 2007)," -- which proposes to amend,the Controlled ... to minors and,create penalties to those who would ...
... America, the,fastest-growing Hispanic television network in the United States, ... this week,s broadcast of "Issues:,Caras y Voces" (Issues: Faces ... Dr. Huerta is the first Latino to assume the ... studied medicine at the University of San,Marcos and Johns ...
... Dec. 18 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... British,Columbia Supreme Court has issued a final order ... (SWX: GALN), through a wholly-owned,Canadian subsidiary, will acquire ... US$26.00 per share in cash., The transaction, ...
... 18 Alsius Corporation,(Nasdaq: ALUS ), which ... announced today that the company has,launched offers to ... opportunity, for a limited time, to exercise the ... terms of the warrants to allow holders to,receive ...
... Royalty Pharma and Northwestern,University announced today that Northwestern ... in Lyrica(R) to Royalty Pharma for $700 million,in ... A portion of the payment to Northwestern will ... chemical compound that serves as the basis for,Lyrica(R)., ...
... SAN DIEGO, Dec. 18 Pacira Pharmaceuticals, ... today announced that,David M. Stack has been ... of the Board of Directors., (Logo: ... currently the CEO and founding partner of ...
Cached Medicine News:Health News:Council for Responsible Nutrition Calls Proposed DHEA Legislation 'A Solution in Search of a Problem' 2Health News:American Cancer Society President Elmer Huerta Shares Inspirational Message on Azteca America's 'Issues: Caras Y Voces' 2Health News:Aspreva receives final court approval for acquisition by Galenica 2Health News:Aspreva receives final court approval for acquisition by Galenica 3Health News:Aspreva receives final court approval for acquisition by Galenica 4Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 2Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 3Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 4Health News:Royalty Pharma Acquires a Portion of Northwestern University's Royalty Interest in Lyrica(R) for $700 Million 2Health News:Royalty Pharma Acquires a Portion of Northwestern University's Royalty Interest in Lyrica(R) for $700 Million 3Health News:Pacira Pharmaceuticals Names David M. Stack CEO and President 2Health News:Pacira Pharmaceuticals Names David M. Stack CEO and President 3
(Date:5/23/2013)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very ... panel meeting for non-thermal shortwave diathermy: The ... Meeting was held on May 21, 2013 in ... the meeting was very narrow, in that the FDA ... application of non-thermal shortwave diathermy for the treatment of ...
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)...  Inhibikase Therapeutics, Inc., an emerging leader in ... present new results on its antiviral program to ... the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, ... the causative agent of Progressive Multifocal Leukoencephalopathy (PML). ... extended release formulation, can clear JC polyomavirus (JCV) ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... Announces Clinical Trial Plans for 4Q07/1Q08, DALLAS, ... ACCP) provided today an update on the clinical,development ... prodrug, and,announced plans for additional human clinical trials ... ongoing clinical trial in recurrent ovarian,cancer patients, designed ...
... ... Study -, ... has initiated a multi-dose, Phase 2a clinical trial with,its monoclonal antibody ... dose-escalation study is,designed to evaluate the safety and tolerability of multiple ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 2Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 3Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 4MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma 2
... The Accustrip Strep A(ll) Test ... immunoassay for the rapid, qualitative ... antigen from throat swabs. The ... as an aid in the ...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
The INRatio meter is a diagnostic Point Of Care system that provides Prothrombin Time (PT) and International Normalized Ratio (INR) results using one drop of fresh capillary whole blood from a finger...
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: